Drug – Share Talk

Angle PLC (AIM:AGL) Molecular characterisation of CTCs

Abm May 27, 2022

PARSORTIX ENABLES MOLECULAR CHARACTERISATION OF CTCS ISOLATED FROM FROZEN SAMPLES IN PATIENTS WITH NON-SMALL CELL LUNG CANCER AND SARCOMA

Angle PLC (AIM:AGL) receives FDA clearance for Parsortix

Abm May 25, 2022

ANGLE ACHIEVES WORLD FIRST WITH FDA CLEARANCE FOR ITS PARSORTIX SYSTEM

Futura Medical PLC (AIM:FUM) MED3000 Collaboration in EEA, UK & Switzerland

Abm May 23, 2022

Futura Announces Collaboration with Cooper Consumer Health to Commercialise MED3000 in EEA, United Kingdom and Switzerland

Omega Diagnostics Gp (AIM:ODX) Placing, Subscription and Open Offer

Abm May 6, 2022

Placing of 50,000,000 New Ordinary Shares and Warrants

Omega Diagnostics Gp (AIM:ODX) Trading Update

Abm April 7, 2022

Omega (AIM: ODX), the specialist medical diagnostics company focused on industry-leading Health & Nutrition and Global Health (CD4 and COVID-19) products, provides the following trading update for the year ended

Poolbeg Pharma PLC (AIM:POLB) Commencement of trading on US OTCQB market

Abm March 30, 2022

Poolbeg Pharma commences trading on OTCQB Market in the United States

Angle PLC (AIM:AGL) Identifying therapeutic targets in TNBC patients

Abm March 25, 2022

PARSORTIX SHOWS POTENTIAL FOR IDENTIFYING THERAPEUTIC TARGETS IN PATIENTS WITH TRIPLE-NEGATIVE BREAST CANCER

Poolbeg Pharma PLC (AIM:POLB) Artificial Intelligence deal signed with CytoReason

Abm March 24, 2022

First time that AI analysis of human challenge trial data is used to identify novel drug targets for influenza

Poolbeg Pharma PLC (AIM:POLB) 2021 Annual Report and 2022 AGM Notice

Abm March 9, 2022

9 March 2022 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’) a clinical-stage infectious disease pharmaceutical company with a unique capital-light clinical model, announces that its Annual Report and

Omega Diagnostics Gp (AIM:ODX) Result of Open Offer

Abm March 1, 2022

Omega (AIM: ODX), the specialist medical diagnostics company focused on industry-leading Health & Nutrition and Global Health (CD4 and COVID-19) products, today announces the results of its Open Offer.